CA
NZ
UK
AU
IND
US
Baxter International (NYSE: BAX) has streamlined its financial reporting structure to reflect a new operating model, reducing its segments from three to two. The changes, effective for the quarter ending June 30, 2026, aim to align resource allocation and performance assessment under the leadership …
Capricor Therapeutics (NASDAQ: CAPR) has finalized a lease for a new facility in San Diego, marking a significant expansion of its operational footprint. The space, spanning approximately 171,000 rentable square feet, will house the company’s headquarters, manufacturing cleanrooms, research labs, and administrative offices. The …
Crescent Biopharma has disclosed preliminary cash reserves for the quarter ended June 30, offering investors a snapshot of its financial position. The biotech firm’s liquidity remains a focal point as it advances its clinical pipeline.
ENvue Medical disclosed a board reshuffle on July 14, 2026, with two longtime members exiting and three individuals stepping into governance roles. The company emphasized that the departures were not driven by any dispute over corporate direction.
American Well Corp (NYSE: AMWL) adjusted its board structure this month, reappointing director Stephen Schlegel to align with exchange requirements. The change follows a resignation and reclassification to ensure balanced representation across the company’s three director classes.
Anika Therapeutics (NASDAQ: ANIK) has finalized a key financing move, extending its revolving credit facility with Bank of America to support long-term operations. The amended agreement provides immediate access to capital while offering flexibility for future growth in the orthopedic and regenerative medicine sectors.
Atrium Therapeutics, Inc. (NASDAQ: RNA) disclosed that its Investigational New Drug filing has been cleared, clearing the path for its upcoming Phase 1/2 study of ATR 1072. The trial aims to address the genetic disorder known as PRKAG2 syndrome, a condition with limited therapeutic …
Two of the healthcare sector’s most prominent companies, Abbott Labs and Pfizer, are managing distinct challenges that have influenced their stock performance. Abbott Labs has experienced a notable decline this year, while Pfizer has contended with shifting demand for some of its key products. …
Alamar Biosciences (ALMR) saw its share price climb sharply after announcing that its NULISA platform, aimed at detecting disease biomarkers, was spotlighted across a wide slate of scientific presentations at the Alzheimer’s Association International Conference.
US inflation showed signs of cooling in June 2026, providing some relief to markets and policymakers after months of elevated price growth. The consumer price index rose 3.5% year-over-year, a moderation that may influence the Federal Reserve’s approach to monetary policy. The data contributed …
Please wait processing your request...